Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Uterine Cervical Neoplasms 2Solid Tumors 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Advanced Malignant Solid Neoplasm 2Vaginal Neoplasms 1Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Previously Treated Non Small Cell Lung Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pinealoma 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Pancreatic Adenocarcinoma 1Meningeal Carcinomatosis 1Medulloblastoma 1Lymphoid Interstitial Pneumonia 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1

Interventions

antineoplaston AS 2-1 3antineoplaston A10 3dactolisib 2Temozolomide 2Irinotecan 2Everolimus 2Bevacizumab 2surufatinib 1spartalizumab 1poly ICLC 1plerixafor 1pasireotide 1fosbretabulin 1cixutumumab 1adavosertib 1Vaccines 1TH 302 1Sunitinib 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1PM 00104 1Lapatinib 1Immunologic Techniques 1Immunoglobulin G 1Genistein 1Fentanyl 1Donepezil 1Disulfides 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroectodermal Tumors, Primitive × adavosertib × Clear all
NCT02095132 2023-09-26

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
76 enrolled 25 charts
CNSSarcoma

Medulloblastoma, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡